TP53 and small cell lung carcinoma: Here, NRF2E79Q-active H596 tumors with RB/P53 mutations (that drive human SCLC) showed trans-differentiation towards SCLC, most likely SCLC-Y type with high YAP expression and low MYC signaling [40].